Merck & Co (MRK.N) is in advanced talks to acquire drugmaker Acceleron Pharma Inc (XLRN.O), the Wall Street Journal reported on Monday, citing people familiar with the matter.
A potential deal could help Merck, which sells the blockbuster cancer drug Keytruda, to add drugs for rare diseases to its pipeline.
Cambridge, Massachusetts-based Acceleron focuses on the discovery, development and commercialization of therapeutics to treat blood-related disorders. It had a market capitalization of $10.89 billion, as of its last close.
A Bloomberg report on Friday said Acceleron was in talks to be acquired for more than $11 billion. Bloomberg had reported that several drugmakers including Merck’s rival Bristol-Myers Squibb Co (BMY.N), which owns 11.5% of Acceleron’s stock, were seen as potential suitors.
Acceleron currently earns royalties from sales of Reblozyl, a drug to treat two blood related disorders, and is developing another treatment for a type of high blood pressure that affects the lungs.
Reblozyl, which is jointly co-promoted by Bristol and Acceleron, brought in sales of $274 million in 2020, according to Bristol Myers.